Markets:

Overview

News

Currencies

International

Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

6.890 -0.190 (-2.68%)

Streaming Delayed Price Updated: 12:14 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Expert Ratings for Bicycle Therapeutics ↗

May 06, 2022

Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:

Via Benzinga

Recap: Bicycle Therapeutics Q1 Earnings ↗

May 05, 2022

Bicycle Therapeutics (NASDAQ:BCYC) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 05, 2022

From Bicycle Therapeutics plc

Via Business Wire

B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33 ↗

April 13, 2022

B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00. Shares of Bicycle Therapeutics...

Via Benzinga

Where Bicycle Therapeutics Stands With Analysts ↗

April 13, 2022

Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022 ↗

April 13, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 11, 2022

Gainers Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million.

Via Benzinga

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

April 11, 2022

From Bicycle Therapeutics plc

Via Business Wire

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗

April 10, 2022

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

Via Benzinga

Why Bicycle Therapeutics Stock Is Soaring Today ↗

April 08, 2022

Via Benzinga

Will Bicycle Therapeutics, With A 25% Gain Today, Take On Pfizer In Covid? ↗

April 08, 2022

Early-stage testing shows promise for this biotech company's Covid antiviral.

Via Investor's Business Daily

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 08, 2022

Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume...

Via Benzinga

Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

April 08, 2022

From Bicycle Therapeutics

Via Business Wire

Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting

April 07, 2022

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

April 06, 2022

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics's Return On Capital Employed Overview ↗

March 04, 2022

Bicycle Therapeutics (NASDAQ:BCYC) brought in sales totaling $3.77 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.88%, resulting in a...

Via Benzinga

What 4 Analyst Ratings Have To Say About Bicycle Therapeutics ↗

March 03, 2022

Analysts have provided the following ratings for Bicycle Therapeutics (NASDAQ:BCYC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Bicycle Therapeutics: Q4 Earnings Insights ↗

March 01, 2022

Bicycle Therapeutics (NASDAQ:BCYC) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

February 09, 2022

From Bicycle Therapeutics plc

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗

February 14, 2022

Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,...

Via Benzinga

Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team

January 05, 2022

From Bicycle Therapeutics plc

Via Business Wire

Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength ↗

December 31, 2021

The list features stocks from diverse sectors as the economy recovers from the pandemic.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 ↗

December 09, 2021

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021 ↗

December 17, 2021

Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ:

Via Benzinga

7 A-Rated Biotechs to Buy for the Long Run ↗

December 03, 2021

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

Via InvestorPlace

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

November 11, 2021

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting

November 09, 2021

From Bicycle Therapeutics plc

Via Business Wire

Looking Into Bicycle Therapeutics's Return On Capital Employed ↗

November 08, 2021

According to Benzinga Pro data, during Q3, Bicycle Therapeutics (NASDAQ:BCYC) posted sales of $4.33 million. Earnings were up 17.27%, but Bicycle Therapeutics still reported an...

Via Benzinga

Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 04, 2021

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression

November 04, 2021

From Bicycle Therapeutics plc

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.